The average (median and range) time from consent to the end of follow up will be calculated from the database presented in the AE tables. All-Cause Mortality will be presented as per the C linicalT rials.gov template as follows (based on a programmed table) : Note: CT.go v Definition of Total all cause m ortality: Total of all anticipated and unanticipated deaths due to any cause . Experimental: AST -VAC2 Affect/At Risk (%) # Events Total All Cause Mortality * Serious Adverse events will be presented as per the C linicalT rials.gov template as follows (based on a programmed table) : Experimental: AST -VAC2 Affect/At Risk (%) # Events Total <AE term> <AE term> <AE term> Other (non -Serious) Adverse events will be presented as per the clinicaltrials.gov template as follows (based on a programmed table) : Frequency Threshold Above Which Other Adverse Events are Reported: 0% Experimental: AST -VAC2 Affect/At Risk (%) # Events Total SM.TEMP.013 version 5 CRUKD/17/003 RAP Version: 2.0 09Mar2023 FINAL 33 <AE term> <AE term> <AE term> SM.TEMP.013 version 5 CRUKD/17/003 RAP Version: 2.0 09Mar2023 FINAL 36 were not evaluable at radiological disease assessment (computerised tomography and/or magnetic resonance imaging) at the End of Vaccination visit according to irRC (Appendix 3 of protocol) . Time Frame: Baseline to End of Vaccination visit ( 30 days post last vaccination ). Measure Type: Count of participants Measure of dispersion/precision: Not applicable To determine the 2 -year overall survival (OS) in patients receiving the AST -VAC2 vaccine. Measurement of overall survival at two years post first vaccination. Measure Title : Overall survival at 2 Years Post First Vaccination Measure Description Number of participants alive at 2 years post their first vaccination . Time Frame: From first AST -VAC2 vaccination to 2 years post first vaccination . Measure Type: Count of participants Measure of dispersion/precision: Not applicable SM.TEMP.013 version 5 CRUKD/17/003 RAP Version: 2.0 09Mar2023 FINAL 37 7.5.1 Outcome Measure 1 – Frequency and causality of AEs and SAEs to AST -VAC2 (Safety Population) The following table will be programmed to provide results for f requency and causality of AEs and SAEs to AST -VAC2 . Arm/Group Title Experimental: AST -VAC2 Frequency and causality of AEs , SAEs and Grade ≥3 AEs to AST - VAC2 Measure type: Number Unit of measure: not applicable Number of participants analysed <N> SAEs <data> Non-serious AEs <data> Grade ≥3 AEs <data> Related SAEs <data> Related non -serious SAEs <data> Related Grade ≥ 3 AEs <data> SM.TEMP.013 version 5 CRUKD/17/003 RAP Version: 2.0 09Mar2023 FINAL 38 7.5.2 Outcome Measure 2 - Number of participants experiencing ISRs by grade (Safety Population) The following table will be programmed to provide results for number of pa rticipants experiencing ISRs Grade 1 to 4. Arm/Group Title Experimental: AST -VAC2 Participants experiencing ISRs Grade 1 to 4 Measure type: Count of participants Unit of measure: participants Number of participants analysed <N> Grade 1 <data> Grade 2 <data> Grade 3 <data> Grade 4 <data> SM.TEMP.013 version 5 CRUKD/17/003 RAP Version: 2.0 09Mar2023 FINAL 39 7.5.3 Outcome Measure 3 – Number of participants showing a durable peripheral immune response (Secondary Immunogenicity Endpoint Population) The following table will be programmed to provide results for the number of pa rticipants with a durable periperal immune response . Arm/Group Title Experimental: AST -VAC2 Participants showing a durable peripheral immune response Measure type: Count of participants Unit of measure: participants Number of participants analysed <N> Durable response <data> Non-durable response <data> Undetermined (baseline sample did not pass acceptance criteria or insufficient timepoints ) <data> SM.TEMP.013 version 5 CRUKD/17/003 RAP Version: 2.0 09Mar2023 FINAL 40 7.5.4 Outcome Measure 4 – Mean fold change over baseline by timepoint (Secondary Immunogenicity Endpoint Population) The following table will be programmed to provide results for the mean fold change from baseline . Arm/Group Title Experimental: AST -VAC2 Overall Number of Participants Analysed <N> Mean fold change over baseline Measure type: Mean Unit of measure: full range Number of participants analysed <N> Week 3 <data> Number of participants analysed <N> Week 4 <data> Number of participants analysed <N> Week 6 <data> Number of participants analysed <N> 2 weeks post last vaccination <data> Number of participants analysed <N> 3 months post first vaccination <data> Number of participants analysed <N> 6 months post first vaccination <data> Number of participants analysed <N> 12 months post first vaccination <data> SM.TEMP.013 version 5 CRUKD/17/003 RAP Version: 2.0 09Mar2023 FINAL 41 7.5.5 Outcome Measure 5 - Tumour response according to Immune -Related Response Criteria (irRC) post vaccination (Response population) The following table will be programmed to provide results for tumour response . Arm/Group Title Experimental: AST -VAC2 Tumour response according to irRC post vaccination Measure type: Count of participants Unit of measure: participants Number of participants analysed <N> Complete response (irCR) <data> Partial response (irPR) <data> Stable disease (irSD) <data> Progressive disease (irPD) <data> Not evaluable (NE) <data> SM.TEMP.013 version 5 CRUKD/17/003 RAP Version: 2.0 09Mar2023 FINAL 42 7.5.6 Outcome Measure 6 – O verall survival at 2 years post first vaccination (Safety Population) The following table will be programmed to provide results for overall survival . Arm/Group Title Experimental: AST -VAC2 Overall survival at 2 years post first vaccination Measure type: Count of participants Unit of measure: participants Number of participants analysed <N> Alive <data> Deceased <data> 7.6 Statistical Analyses No statistical analyses are to be performed on the primary or secondary endpoints . SM.TEMP.013 version 5 CRUKD/17/003 RAP Version: 2.0 09Mar2023 FINAL 43 8.